Oncology drug development
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- PHARMA MAR SA
Spanish biopharma company specializing in marine-derived anticancer drugs, marine enzyme discovery, and bio-based compound engineering.
“Participated in ITCC-P4, a pediatric preclinical platform spanning solid tumors, brain tumors, and biomarker-driven relapse studies.”
PrimaryES4 projects - RHOVAC APS
Danish biotech SME developing RV001, a therapeutic vaccine targeting metastatic prostate cancer through immunotherapy.
“Successful SME Instrument Phase 1 to Phase 2 progression indicates structured preclinical/clinical development capability within oncology.”
SMEDK2 projects - APPLIED RESEARCH USING OMIC SCIENCES SL
Barcelona biotech SME developing small-molecule drug candidates for chemoresistant and rare cancers using omics-driven target identification.
“Both META-CAN (cancer metabolism/immune connections) and BERMES (berberine derivative for mesothelioma) center on developing therapeutic strategies for cancer.”
PrimarySMEES2 projects